Hepatitis-C-Therapie vor und nach Nierentransplantation

The implementation of direct acting antiviral agents (DAA) led to a paradigm shift in the treatment of hepatitis C virus (HCV) infections. Kidney transplant patients with HCV infections in particular nowadays benefit from DAA treatment with few side effects and high cure rates over 95%. The new Kidney Disease: Improving Global Outcomes (KDIGO) guidelines from 2022 even advocate the transplantation of HCV viremic kidneys into HCV-naïve recipients if early postoperative DAA treatment is administered for 4 weeks up to a maximum of 12 weeks. This article reviews the risks of HCV infections before and after renal transplantation, highlights the opportunities and risks of DAA treatment for kidney transplant recipients and draws attention to special characteristics and limitations.